

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- | | | |
|-------------------------------------|-------------------------------------|--|
| ☐ | ☒ | The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| ☐ | ☒ | A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| ☐ | ☒ | The statistical test(s) used AND whether they are one- or two-sided
<i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i> |
| ☒ | ☐ | A description of all covariates tested |
| ☒ | ☐ | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| ☐ | ☒ | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| ☐ | ☒ | For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
<i>Give P values as exact values whenever suitable.</i> |
| ☒ | ☐ | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| ☒ | ☐ | For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| ☒ | ☐ | Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection Images were collected using SoftWoRx (Applied Precision), LAS X (Leica) and ZEN (Zeiss).

Data analysis Images were analyzed by FIJI distribution of ImageJ. Statistical analyses were performed with Microsoft Excel software and GraphPad Prism 9.0. For deconvolution, Huygens essential software (SVI; Scientific Volume Imaging) was used.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The data that support the findings of this study are available from the corresponding author upon request. The RNA-seq data analyzed in this study have been deposited in the DDBJ database under the accession number PRJDB20465 (<https://ddbj.nig.ac.jp/search/entry/bioproject/PRJDB20465>).

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender

Use the terms *sex* (biological attribute) and *gender* (shaped by social and cultural circumstances) carefully in order to avoid confusing both terms. Indicate if findings apply to only one sex or gender; describe whether sex and gender were considered in study design; whether sex and/or gender was determined based on self-reporting or assigned and methods used. Provide in the source data disaggregated sex and gender data, where this information has been collected, and if consent has been obtained for sharing of individual-level data; provide overall numbers in this Reporting Summary. Please state if this information has not been collected. Report sex- and gender-based analyses where performed, justify reasons for lack of sex- and gender-based analysis.

Reporting on race, ethnicity, or other socially relevant groupings

Please specify the socially constructed or socially relevant categorization variable(s) used in your manuscript and explain why they were used. Please note that such variables should not be used as proxies for other socially constructed/relevant variables (for example, race or ethnicity should not be used as a proxy for socioeconomic status). Provide clear definitions of the relevant terms used, how they were provided (by the participants/respondents, the researchers, or third parties), and the method(s) used to classify people into the different categories (e.g. self-report, census or administrative data, social media data, etc.) Please provide details about how you controlled for confounding variables in your analyses.

Population characteristics

Describe the covariate-relevant population characteristics of the human research participants (e.g. age, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."

Recruitment

Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.

Ethics oversight

Identify the organization(s) that approved the study protocol.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

No statistical method was used to predetermine sample size.

Data exclusions

No data were excluded from the analyses.

Replication

Reproducibility was confirmed. The number of experiments is described in the figure legends.

Randomization

We assessed cells from several fields for each experiment. The field were chosen randomly. Once a field was determined, we counted all cells which match the criteria within the field.

Blinding

The investigators were not blinded to the sample ID during experiments and outcome assessment because the cells in randomly selected area were analyzed objectively.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
☐	☒ Antibodies
☐	☒ Eukaryotic cell lines
☒	☐ Palaeontology and archaeology
☒	☐ Animals and other organisms
☒	☐ Clinical data
☒	☐ Dual use research of concern
☒	☐ Plants

Methods

n/a	Involved in the study
☒	☐ ChIP-seq
☒	☐ Flow cytometry
☒	☐ MRI-based neuroimaging

Antibodies

Antibodies used

The following primary antibodies were used in this study:
 rabbit antibodies against Cep192 (Bethyl Laboratories, A302–324A, IF 1:1000), C-Nap1 (Proteintech, 14498-1-AP, IF 1:1000), Cdt1 (Abcam, ab202067, IF 1:500), Cdc6 (Abcam, ab109315, WB 1:100), RFP-tag (MBP, PM005, IF 1:1000), CP110 (Proteintech, 12780-1-AP, IF 1:500), Cep57 (GeneTex, GTX115931, IF 1:1000), Cep57L1 (Proteintech, 24957-1-AP, IF 1:500), γ -Tubulin (Merck, T5192, IF 1:1000), PCNT (Abcam, ab4448, IF 1:2000), Cep152 (Bethyl Laboratories, A302–480A, IF 1:1000), Cep97 (Novus Biologicals, NPB1-83591 IF 1:500), CENP-F (Bethyl Laboratories, A301–617A IF 1:1000), Phospho-Chk1 (S296) (Abcam, ab79758, WB 1:100), Phospho-Chk1 (S345) (Cell Signaling Technology, 2348, WB 1:100), Cyclin-B1 (Cell Signaling Technology, 4138, IF 1:200, WB 1:1000), BLM (Abcam, ab2179, IF 1:250), ATR (Bethyl Laboratories, A300-137A, WB 1:500), ETAA1 (Abcam, ab192402, WB 1:100), TopBP1 (Abcam, ab2402, WB 1:1000), mNeonGreen-tag (Cell Signaling Technology, 53061, WB 1:100), p97 (VCP; GeneTex, GTX101089, IF 1:1000), Cdc45 (Cell Signaling Technology, 11881, IF 1:200, WB 1:500), LRR1 (Atlas antibodies, HPA069364, IF 1:200, WB 1:1000) and MCM3 (Cell Signaling Technology, 4012, WB 1:1000), Emi1 (Proteintech, 10872-1-AP, WB 1:1000);
 mouse antibodies against FLAG-tag (Merck, F1804, IF 1:1000, WB 1:1000), centrin-2 (Merck, 20H5, IF 1:1000), PCNA (Santa Cruze Biotechnology, sc-56, IF 1:1000, WB 1:500), CENP-F (Mitosin; BD Biosciences Pharmingen, 610768, IF 1:1000), Cdc6 (Santa Cruze Biotechnology, sc-13136, IF 1:200), HSP90 (BD Transduction Laboratories, 610418, WB 1:5000), Cdh1 (Fzr1; Abcam, ab89535, IF 1:300), HsSAS-6 (Santa Cruze Biotechnology, sc-81431, IF 1:1000), EB1 (BD Transduction Laboratories, 610534, IF 1:500), Phospho-Plk1 (T210) (Abcam, ab39068, IF 1:300), Chk1 (Santa Cruze Biotechnology, sc-8408, WB 1:1000), α -Tubulin (Merck, DM1A, IF 1:1000, WB 1:5000), HA-tag (BioLegend, 901501, WB 1:1000), mNeonGreen-tag (Proteintech, 32F6, IF 1:500), Cyclin-E1 (Cell Signaling Technology, 4129, WB 1:1000), Cyclin-A2 (Cell Signaling Technology, 4656, WB 1:1000), Histone H3 (Santa Cruze Biotechnology, sc-517576, WB 1:5000), LaminB1 (Santa Cruze Biotechnology, sc-374015, WB 1:100) and γ -Tubulin-Alexa Fluor 647 (Abcam, ab191114, IF 1:500);
 rat antibodies against centrin2 (BioLegend, 698602, IF 1:500) and PCNA (Abcam, ab252848, IF 1:2000).

The following secondary antibodies were used: Alexa Fluor 488 goat anti-mouse IgG (H+L) (Molecular Probes, A-11001, 1:1000), Alexa Fluor 568 goat anti-rabbit IgG (H+L) (Molecular Probes, A-11011, 1:1000), Alexa Fluor 647 goat anti-rat IgG (H+L) (Invitrogen, A21247, 1:1000) for IF; Goat polyclonal antibodies-horseradish peroxidase against mouse IgG (Promega, W402B, 1:5000) and rabbit IgG (Promega, W401B, 1:5000) for WB.

Validation

The validation of each primary antibody was performed by IF or WB using knockdown and/or knockout samples.

Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)	HeLa, U2OS, PANC-1, and HEK293T cells were obtained from the ECACC (European collection of cell cultures) and RPE-1 cells were obtained from the ATCC (American Type Culture Collection). hTERT immortalized primary fibroblasts derived from patients with DONSON mutations were described in the previous study (Reynold et al., 2017).
Authentication	Cell lines were examined for their morphology by microscopy.
Mycoplasma contamination	All cell lines were tested for mycoplasma contamination and found negative.
Commonly misidentified lines (See ICLAC register)	No commonly misidentified cell lines were used.

Plants

Seed stocks

Report on the source of all seed stocks or other plant material used. If applicable, state the seed stock centre and catalogue number. If plant specimens were collected from the field, describe the collection location, date and sampling procedures.

Novel plant genotypes

Describe the methods by which all novel plant genotypes were produced. This includes those generated by transgenic approaches, gene editing, chemical/radiation-based mutagenesis and hybridization. For transgenic lines, describe the transformation method, the number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the editor used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor was applied.

Authentication

Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to assess the effect of a mutation and, where applicable, how potential secondary effects (e.g. second site T-DNA insertions, mosaicism, off-target gene editing) were examined.